Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From IXICO Plc
Scrip Asks…What Does 2023 Hold For Biopharma? Part 8: Therapeutic Area Advances
Neuroscience and oncology fuel high hopes for therapeutic R&D progress among 90-plus surveyed biopharma industry leaders.
Sanofi Goes All In For Type 1 Diabetes With Provention Buy
Sanofi is taking full control of the recently approved type 1 diabetes prevention therapy Tzield by splashing out $2.9bn to acquire partner Provention.
Requests For EMA PRIME Designation Fall But Improvements Are On The Way
While the European Medicines Agency and industry speculate as to why 2022 saw far fewer applications for a place on the priority medicines scheme for drugs for unmet medical needs, they are enthusiastic about improvements to the initiative that are set to be trialed soon.
Cell Therapy Developers Dominate China VC/PE Funding In October
Six Chinese biotechs raise a combined $141m in major financing deals backed by venture capital and private equity firms.
- Contract Research, Toxicology Testing-CRO
- Research, Analytical Equipment & Supplies
Diagnostic Imaging Equipment & Supplies
- Digital Imaging
- MRI, NMR
- Diagnostic Imaging Equipment & Supplies
- Other Names / Subsidiaries
- IXICO Technologies Inc.
- Optimal Medicine Inc.
- Phytopharm plc
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.